Skip to content

Observational clinical study of the CE-marked cemented A2(R) short stem

Observational clinical study of the CE-marked cemented A2(R) short stem - A2zem

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00025152
Enrollment
140
Registered
2021-04-30
Start date
2021-09-22
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M16 M06 M87 S72

Interventions

Group 1: The study contains the following phases: - a screening phase / preoperative phase (investigation 1)
- a hospitalization phase (examination 2)
- a follow-up phase (examinations 3 - 7): after 1 year as well as after 3, 5, 7 and 10 years For examination 1 (up to 30 days before surgery), the following steps are envisaged: - Screening: patients

Sponsors

ARTIQO GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The subjects require a primary hip joint replacement and are candidates for an endoprosthetic fitting with the cemented A2® short stem in accordance with the purpose and indications and contraindications of the currently valid version of the instructions for use of the product. There is no restriction to certain indications within the intended use. Indications and contraindications according to the instructions for use of the cemented A2® hip stem are as follows: Indications - Patients with advanced wear of the hip joint due to degenerative and post-traumatic arthrosis or rheumatoid arthritis - Avascular necrosis of the femoral head - Acute traumatic fracture of the femoral head or neck, as long as stable anchorage of the implant is guaranteed. Contraindications - Acute or chronic infections, local or systemic - Severe muscular, nervous or vascular diseases that may endanger the affected extremities - Fractures tangential to or extending beyond the base of the femoral neck which radiate into the trochanteric region or the calcar. - Missing or deficient bone substance, which endangers the stable fit of the prosthesis - Previous operations which no longer provide the intended support - Pronounced coxa valga with a femoral neck angle >145° - Pronounced coxa vara with a femoral neck angle 30 2. Subjects are willing and physically and mentally able to participate in the clinical trial and intend to be available for the scheduled follow-up visits. 3. Normal motor function of the lower extremities, documented by clinical examination and absence of anamnestic evidence of neurological disease with alteration of motor function. 4. Subjects with age = 18 years. 5. Subjects with a life expectancy of >5 years, as far as assessable by the investigator.

Exclusion criteria

Exclusion criteria: a) Pre-operative exclusion criteria 1. Previous bony or soft tissue surgery on the affected proximal femur (e.g., varicose osteotomy). Arthroscopic surgery is excluded. 2. Infection of the affected hip joint or systemic infection. 4. CCD angle above 145°. 5. CCD angle below 120°. 6. Proven allergy to components of the implanted prosthesis. 7. Known neurological disease with alteration of motor function, neurological function, as well as neurological or mental illnesses, which may affect an objective assessment of the patient's state of health or an evaluation of his hip joint. 8. Pregnant or lactating women and those who are planning to become pregnant in the next to 2 years (+3 weeks) according to the index procedure. 9. BMI over 32 10. Known alcoholism or other relevant addictive diseases. b) Intra-operative exclusion criteria 1. Intra-operative circumstances that would allow implantation of a prosthesis other than the type of prosthesis envisaged in the study. (as determined by the surgeon).

Design outcomes

Primary

MeasureTime frame
The primary endpoint for the study is the revision rate at ten years postoperatively.

Secondary

MeasureTime frame
Secondary endpoints include the following postoperative outcomes: - Evaluation of function, range of motion, and pain using the Harris Hip Score (HHS) - Evaluation of pain and function using Hip Dysfunction and Osteoarthritis Outcome Score Short Form (HOOS-PS) - Evaluation of residual symptoms using the Forgotten Joint Score (FJS-12) - radiographic changes, defined as radiolucent lines, osteolysis, remodeling of the cortical bone, loosening of the implant and (macroscopically visible) migration of the stem - any revisions - Intraoperative, early postoperative, and postoperative complications

Countries

Germany

Contacts

Public ContactDirk Ganzer

Dietrich-Bonhoeffer-Klinikum Klinik für Orthopädie und Unfallchirurgie

GanzerD@dbknb.de0395/775-3550

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026